Skip to main content
Erschienen in: Rheumatology International 1/2021

17.11.2020 | COVID-19 | Expert Opinion Zur Zeit gratis

COVID-19 pandemic in Japan

verfasst von: Olga Amengual, Tatsuya Atsumi

Erschienen in: Rheumatology International | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

The disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus Disease-2019 (COVID-19), is a global emergency. The first case of COVID-19 was confirmed in Japan in January 2020, a second outbreak of infection occurred in mid-March and a third peak at the beginning of August. The COVID-19 phenotype was milder in Japan than in other countries, although the restrictive measures applied in the country have not been as strict as in other places. Factors related to a possible reduced susceptibility to the pulmonary manifestations of SARS-CoV-2 may have contributed to better outcomes and lower mortality in Japan.
Literatur
1.
Zurück zum Zitat Sawalha AH, Manzi S (2020) Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol 7:S117–S120CrossRef Sawalha AH, Manzi S (2020) Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol 7:S117–S120CrossRef
6.
Zurück zum Zitat Iwasaki A, Grubaugh ND (2020) Why does Japan have so few cases of COVID-19? EMBO Mol Med 12:e12481CrossRef Iwasaki A, Grubaugh ND (2020) Why does Japan have so few cases of COVID-19? EMBO Mol Med 12:e12481CrossRef
7.
Zurück zum Zitat D’Antiga L (2020) Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl 26:832–834CrossRef D’Antiga L (2020) Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl 26:832–834CrossRef
9.
Zurück zum Zitat Yamada Z, Nanki T (2020) COVID-19 in a patient with rheumatoid arthritis during tocilizumab treatment. J Clin Rheumatol 26:240–241CrossRef Yamada Z, Nanki T (2020) COVID-19 in a patient with rheumatoid arthritis during tocilizumab treatment. J Clin Rheumatol 26:240–241CrossRef
10.
Zurück zum Zitat Mokuda S, Tokunaga T, Masumoto J, Sugiyama E (2020) Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin 6 through STAT3 signaling in synovial tissues. J Rheumatol 47:1593–1595CrossRef Mokuda S, Tokunaga T, Masumoto J, Sugiyama E (2020) Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin 6 through STAT3 signaling in synovial tissues. J Rheumatol 47:1593–1595CrossRef
11.
Zurück zum Zitat Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N et al (2020) Care for patients with rheumatic diseases during COVID-19 pandemic: a position statement from APLAR. Int J Rheum Dis 23:717–722CrossRef Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N et al (2020) Care for patients with rheumatic diseases during COVID-19 pandemic: a position statement from APLAR. Int J Rheum Dis 23:717–722CrossRef
12.
Zurück zum Zitat Oku K, Atsumi T (2019) Rheumatology practice in Japan: challenges and opportunities. Rheumatol Int 39:1499–1505CrossRef Oku K, Atsumi T (2019) Rheumatology practice in Japan: challenges and opportunities. Rheumatol Int 39:1499–1505CrossRef
13.
Zurück zum Zitat Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68CrossRef Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68CrossRef
14.
Zurück zum Zitat Ito S, Sumida T (2004) Interstitial lung disease associated with leflunomide. Intern Med 43:1103–1104CrossRef Ito S, Sumida T (2004) Interstitial lung disease associated with leflunomide. Intern Med 43:1103–1104CrossRef
15.
Zurück zum Zitat Kamata Y, Nara H, Kamimura T, Haneda K, Iwamoto M, Masuyama J et al (2004) Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43:1201–1204CrossRef Kamata Y, Nara H, Kamimura T, Haneda K, Iwamoto M, Masuyama J et al (2004) Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43:1201–1204CrossRef
16.
Zurück zum Zitat Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T et al (2009) Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48:1069–1072CrossRef Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T et al (2009) Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48:1069–1072CrossRef
17.
Zurück zum Zitat Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY et al (2007) Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 56:2094–2096CrossRef Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY et al (2007) Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 56:2094–2096CrossRef
18.
Zurück zum Zitat Suissa S, Hudson M, Ernst P (2006) Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 54:1435–1439CrossRef Suissa S, Hudson M, Ernst P (2006) Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 54:1435–1439CrossRef
19.
Zurück zum Zitat Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280 e278CrossRef Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280 e278CrossRef
22.
Zurück zum Zitat Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 382:2327–2336CrossRef Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 382:2327–2336CrossRef
24.
Zurück zum Zitat Doi K, Ikeda M, Hayase N, Moriya K, Morimura N, the COVID-UTH study group (2020) Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19 a case series. Crit Care 24:392CrossRef Doi K, Ikeda M, Hayase N, Moriya K, Morimura N, the COVID-UTH study group (2020) Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19 a case series. Crit Care 24:392CrossRef
25.
Zurück zum Zitat Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T (2020) Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases. J Infect Chemother 26:625–632CrossRef Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T (2020) Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases. J Infect Chemother 26:625–632CrossRef
Metadaten
Titel
COVID-19 pandemic in Japan
verfasst von
Olga Amengual
Tatsuya Atsumi
Publikationsdatum
17.11.2020
Verlag
Springer Berlin Heidelberg
Schlagwort
COVID-19
Erschienen in
Rheumatology International / Ausgabe 1/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04744-9

Weitere Artikel der Ausgabe 1/2021

Rheumatology International 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.